biocon

Biocon gets 8 observations for 2 new biologics manufacturing units in Bengaluru

The company is confident of addressing these observations effectively through a Corrective and Preventive Action (CAPA) plan, expeditiously, it added.

Biocon enters into pact with CMS to sell 3 generic products in China

Biocon will be responsible for the development, manufacturing and supply of the products while CMS will be responsible for registration and commercialisation of the products in China.

Trade cautiously, markets will take cue from IIP and CPI numbers

Index of Industrial Production and Consumer Price Index data will be released on September 12.

Temasek, True North and CPPIB in investment talks for stake in Biocon arm: Report

Founded in 2016, Biocon Biologics India (BBIL) is reported to be the fastest-growing division within Biocon, with a 97 percent growth in revenue to Rs 1,516 crore in FY19 compared to FY18.

Biocon's partner Mylan launches first biosimilar of trastuzumab in Australia

The company will be selling the drug under brand name Ogivri, which will be used for the treatment of HER2 sub-type breast cancer and metastatic stomach cancer.

Buy Biocon; target of Rs 330: ICICI Direct

ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 330 in its research report dated July 26, 2019.

Biocon Standalone June 2019 Net Sales at Rs 480.80 crore, down 28.47% Y-o-Y

Biocon Consolidated June 2019 Net Sales at Rs 1,465.90 crore, up 30.44% Y-o-Y

Biocon stock nosedives as rival launches biosimilar of Herceptin in US

The biosimilar launched by Amgen and Allergan hit the Biocon scrip, which dropped 8.17 percent and was trading at Rs 241.55 on the BSE at 3 pm.

Market Headstart: Nifty likely to open flat; 3 stocks which could give 8-10% return

Trends on SGX Nifty indicate a flat to negative opening for the broader index in India, a fall of 7.5 points or 0.06 percent. Nifty futures were trading around 11,539-level on the Singaporean Exchange.

USFDA issues 12 observations for 3 Biocon units in Malaysia

As per the USFDA, the Form 483 notifies the company's management of objectionable conditions after the conclusion of an inspection.

Biocon hits 52-week low despite getting CGMP from EU regulator for Bengaluru unit

The European agency inspected Bengaluru unit in March 2019.

Biocon falls 2% despite strong Q4 earnings

At 1114 hrs, Biocon was quoting Rs 606.50, down 2.15 percent on the BSE.

Buy Biocon; target of Rs 730: ICICI Direct

ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 730 in its research report dated April 26, 201

Biocon Consolidated March 2019 Net Sales at Rs 1,528.80 crore, up 30.72% Y-o-Y

Biocon Standalone March 2019 Net Sales at Rs 763.90 crore, up 17.87% Y-o-Y

Riding on biosimilar sales, Biocon Q4 profit up 64% at Rs 214 crore

Total revenue during the quarter grew by 26 percent to Rs 1,557 crore.

Biocon Q4 PAT seen up 35.2% YoY to Rs. 176.2 cr: Kotak

Net Sales are expected to increase by 31.6 percent Y-o-Y (down 0.1 percent Q-o-Q) to Rs. 1,538.7 crore, according to Kotak.

Biocon gets 6 observations from USFDA after inspection of its Bengaluru plant

'The inspection at the Bengaluru facility took place between February 25-March 5, resulting in a Form 483 with six observations,' it added.

Biocon appoints Christiane Hamacher as CEO of Biocon Biologics India

Hamacher comes with more than 20 years of leadership experience in both strategic and operational roles across the value chain in global pharma spanning Asia, Europe and the US, Biocon said in a BSE filing.

Cash Market | Biocon at inflection point, can post a sharp rally

Biocon is at the confluence of multiple technical indicators and post a smart rally

Buy Biocon; target of Rs 760: ICICI Direct

ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 760 in its research report dated January 25, 2019.

Biocon trades flat despite strong Q3 results

Biocon's Q3 net profit more than doubled, rising 136.34 percent YoY to Rs 217.2 crore.

Biocon Q3 net profit zooms over twofold to Rs 217.2 cr

Revenues from the biologics vertical, that comprises biosimilars, rose 136 percent to Rs 449 crore driven by the biosimilar Pegfilgrastim gaining market share in the US.

Biocon Standalone December 2018 Net Sales at Rs 739.70 crore, up 24.93% Y-o-Y